Related references
Note: Only part of the references are listed.PD-L1 expression by Tumor Proportion Score (TPS) and Combined Positive Score (CPS) are similar in non-small cell lung cancer (NSCLC)
Pedro De Marchi et al.
JOURNAL OF CLINICAL PATHOLOGY (2021)
T cell exhaustion is associated with the risk of papillary thyroid carcinoma and can be a predictive and sensitive biomarker for diagnosis
Chumeng Zhu et al.
DIAGNOSTIC PATHOLOGY (2021)
Association between PD-L1 expression and lymph node metastasis in cutaneous squamous cell carcinoma
Shiori Kamiya et al.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2020)
Changes in Treg numbers and activity in papillary thyroid carcinoma with and without Hashimoto's thyroiditis
Na Zhao et al.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH (2020)
Hashimoto's thyroiditis attenuates progression of papillary thyroid carcinoma: deciphering immunological links
Oksana Sulaieva et al.
HELIYON (2020)
Combination of CTLA-4 and PD-1 blockers for treatment of cancer
Anand Rotte
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC)
Lorena Incorvaia et al.
ADVANCES IN THERAPY (2019)
Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study
S. Adams et al.
ANNALS OF ONCOLOGY (2019)
CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A review
Bagher Farhood et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
Chronic lymphocytic thyroiditis (CLT) has a positive prognostic value in papillary thyroid cancer (PTC) patients: the potential key role of Foxp3+T lymphocytes
T. Pilli et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2018)
Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer
Ming Li et al.
BMC CANCER (2018)
In papillary thyroid carcinoma, expression by immunohistochemistry of BRAF V600E, PD-L1, and PD-1 is closely related
Yanhua Bai et al.
VIRCHOWS ARCHIV (2018)
Expression of LAG-3 and efficacy of combination treatment with anti-LAG-3 and anti-PD-1 monoclonal antibodies in glioblastoma
Sarah Harris-Bookman et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
Impact of oncogenic pathways on evasion of antitumour immune responses
Stefani Spranger et al.
NATURE REVIEWS CANCER (2018)
Comprehensive screening for PD-L1 expression in thyroid cancer
Soomin Ahn et al.
ENDOCRINE-RELATED CANCER (2017)
Programmed Cell Death Ligand (PD-L1) Expression in Stage II and III Lung Adenocarcinomas and Nodal Metastases
Hironori Uruga et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
PD-L1 and PD-1 expression are correlated with distinctive clinicopathological features in papillary thyroid carcinoma
Yanhua Bai et al.
DIAGNOSTIC PATHOLOGY (2017)
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
J. M. Michot et al.
EUROPEAN JOURNAL OF CANCER (2016)
Tumor-Infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic Thyroid Cancer
Jill J. Bastman et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2016)
Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study
David F. McDermott et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Current Status and Future Directions of the Immune Checkpoint Inhibitors Ipilimumab, Pembrolizumab, and Nivolumab in Oncology
Meagan S. Barbee et al.
ANNALS OF PHARMACOTHERAPY (2015)
IL10 and PD-1 Cooperate to Limit the Activity of Tumor-Specific CD8+ T Cells
Z. Sun et al.
CANCER RESEARCH (2015)
PD-1 blockade therapy in renal cell carcinoma: Current studies and future promises
F. Massari et al.
CANCER TREATMENT REVIEWS (2015)
Enhanced T-Cell Immunity to Osteosarcoma Through Antibody Blockade of PD-1/PD-L1 Interactions
Danielle M. Lussier et al.
JOURNAL OF IMMUNOTHERAPY (2015)
Analysis of regulatory T cells frequency in peripheral blood and tumor tissues in papillary thyroid carcinoma with and without Hashimoto's thyroiditis
Y. Liu et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2015)
CD8+tumour-infiltrating lymphocytes and COX2 expression may predict relapse in differentiated thyroid cancer
Lucas Leite Cunha et al.
CLINICAL ENDOCRINOLOGY (2015)
Lymphocytic profiling in thyroid cancer provides clues for failure of tumor immunity
Shahnawaz Imam et al.
ENDOCRINE-RELATED CANCER (2014)
Distribution of Lymphocyte Subpopulations in Thyroid Glands of Human Autoimmune Thyroid Disease
Bingbing Zha et al.
JOURNAL OF CLINICAL LABORATORY ANALYSIS (2014)
BRAFV600E in Papillary Thyroid Carcinoma Is Associated with Increased Programmed Death Ligand 1 Expression and Suppressive Immune Cell Infiltration
Trevor E. Angell et al.
THYROID (2014)
Tumor-infiltrating lymphocytes in breast cancer A new predictor for responses to therapy
Yasmin Issa-Nummer et al.
ONCOIMMUNOLOGY (2014)
Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer
Mario Sznol et al.
CLINICAL CANCER RESEARCH (2013)
Regulatory T cells and plasmacytoid dendritic cells contribute to the immune escape of papillary thyroid cancer coexisting with multinodular non-toxic goiter
Hang Yu et al.
ENDOCRINE (2013)
Infiltration of a mixture of immune cells may be related to good prognosis in patients with differentiated thyroid carcinoma
Lucas L. Cunha et al.
CLINICAL ENDOCRINOLOGY (2012)
Foxp3 expression is associated with aggressiveness in differentiated thyroid carcinomas
Lucas Leite Cunha et al.
CLINICS (2012)
Phenotypical Analysis of Lymphocytes with Suppressive and Regulatory Properties (Tregs) and NK Cells in the Papillary Carcinoma of Thyroid
Foteini Gogali et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
The Immune Score as a New Possible Approach for the Classification of Cancer
Jerome Galon et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2012)
Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
Janis M. Taube et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Ipilimumab
Vernon K. Sondak et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Interferon-γ and tumor necrosis factor-α induce an immunoinhibitory molecule, B7-H1, via nuclear factor-κB activation in blasts in myelodysplastic syndromes
Asaka Kondo et al.
BLOOD (2010)
Tumor-Associated Lymphocytes and Increased FoxP3+ Regulatory T Cell Frequency Correlate with More Aggressive Papillary Thyroid Cancer
Jena D. French et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Subclassification of non-solid-type papillary thyroid carcinoma identification of high-risk group in common type
Yanhua Bai et al.
CANCER SCIENCE (2008)
Regulatory T cells, tumour immunity and immunotherapy
WP Zou
NATURE REVIEWS IMMUNOLOGY (2006)
Expression of galectin-3 in normal and malignant thyroid tissue by quantitative PCR and immunohistochemistry
J Feilchenfeldt et al.
MODERN PATHOLOGY (2003)
Papillary thyroid carcinomas from young adults and children contain a mixture of lymphocytes
J Modi et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
HD Dong et al.
NATURE MEDICINE (2002)
Share Paper
